Overview
- Eli Lilly announced it is acquiring three vaccine-focused companies—Curevo, LimmaTech Biologics AG, and Vaccine Company—for a combined $3.8 billion to establish an infectious-disease presence.
- Two GLP-1 drugs, Mounjaro and Zepbound, drove roughly $12.8 billion of revenue in the first quarter of 2026 with year-over-year growth near 125% and 80% respectively, making the class Lilly's main near-term cash engine.
- The company has also added a new oral GLP-1 pill, Foundayo, to its near-term product mix that investors will watch alongside Mounjaro and Zepbound.
- Lilly and analysts say the vaccine deals will be largely inconsequential to short-term results as management uses current GLP-1 cash flow to diversify away from the risk of future patent loss and competitive erosion.
- Longer term the purchases aim to seed a slower-to-payoff infectious-disease pipeline, so investors should monitor clinical progress, regulatory milestones, and how quickly the new units can convert R&D into commercial products.